Biogen and Eisai to discontinue phase 3 ENGAGE and EMERGE trials of aducanumab
Biogen and Eisai, Co. announced the decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE, designed to evaluate the efficacy and safety of aducanumab in patients with mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. March 21, 2019